296 related articles for article (PubMed ID: 19568080)
1. Botox therapy for ischemic digits.
Neumeister MW; Chambers CB; Herron MS; Webb K; Wietfeldt J; Gillespie JN; Bueno RA; Cooney CM
Plast Reconstr Surg; 2009 Jul; 124(1):191-201. PubMed ID: 19568080
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
3. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
4. Botulinum Toxin A Salvage of Ischemic Hand Trauma.
Laarakker AS; Borah G
Plast Reconstr Surg; 2020 Jan; 145(1):161-164. PubMed ID: 31881617
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
6. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Neumeister MW
J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
Uppal L; Dhaliwal K; Butler PE
J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
[TBL] [Abstract][Full Text] [Related]
9. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
[TBL] [Abstract][Full Text] [Related]
10. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
[TBL] [Abstract][Full Text] [Related]
12. Management of vasospastic disorders with botulinum toxin A.
Van Beek AL; Lim PK; Gear AJL; Pritzker MR
Plast Reconstr Surg; 2007 Jan; 119(1):217-226. PubMed ID: 17255677
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
14. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
Quintana Castanedo L; Feito Rodríguez M; Nieto Rodríguez D; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Dermatol Surg; 2021 Jan; 47(1):61-64. PubMed ID: 32371783
[TBL] [Abstract][Full Text] [Related]
15. Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection.
Navarro EP; Cañas CA; Tobón GJ
Rheumatology (Oxford); 2016 Jul; 55(7):1216. PubMed ID: 27155203
[No Abstract] [Full Text] [Related]
16. 25. Ischemic pain in the extremities and Raynaud's phenomenon.
Devulder J; van Suijlekom H; van Dongen R; Diwan S; Mekhail N; van Kleef M; Huygen F
Pain Pract; 2011; 11(5):483-91. PubMed ID: 21435165
[TBL] [Abstract][Full Text] [Related]
17. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
Zhao H; Lian Y
Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
[TBL] [Abstract][Full Text] [Related]
18. The Use of Botulinum Toxin in Raynaud Phenomenon: A Comprehensive Literature Review.
Lawson O; Sisti A; Konofaos P
Ann Plast Surg; 2023 Jul; 91(1):159-186. PubMed ID: 37450876
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Raynaud's phenomenon with botulinum toxin type A.
Zhang X; Hu Y; Nie Z; Song Y; Pan Y; Liu Y; Jin L
Neurol Sci; 2015 Jul; 36(7):1225-31. PubMed ID: 25616446
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
